Trivedon is an anti-ischemic metabolic agent and inhibits fatty acid oxidation,meaning that it improves myocardial glucose utilization thorough inhibition of fatty acid metabolism.

In patients with ischaemic heart disease,trimetazidine acts as a metabolic agent,preserving the myocardial high-energy phosphate intracellular levels. Anti-ischemic effects are achieved without concomitant hemodynamic effects.

Trivedon is indicated in addults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies.

Trimetazidine has been assessed in several randomised studies as a treatment for ischaemic heart. All these studies demonstrate that is an effective product to protect the heart from the deleterious consequences of ischaemia by switching cardiac metabolism from fatty acid oxidation to glucose oxidation